Ep. 171 - 2Q Markets Preview, Abortion Drug Rulings, Gilead Oncology
BioCentury This Week
00:00
Gilead's Ambitions for a Top 10 Cancer Company
Gilead has been building an oncology franchise for more than a decade notably via the $12 billion acquisition of Kite six years ago and it's $21 billion take out of immunometrics that was in 2020. The company has shown it can create a blockbuster from its CAR T technology but it has an ambitious goal of becoming a top 10 cancer company by the end of this decade. If you're a biotech looking for a partner yeah Gilead's a player.
Transcript
Play full episode
